ESMO 2025 – Roche sticks it to its SERD rivals
But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.
ESMO 2025 preview – Merck hopes for Daiichi redemption
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
Neither Arvinas nor Pfizer now wants vepdegestrant
So who else could be interested in the oestrogen degrader?
Astellas and Amgen join the pan-KRAS push
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
Arvinas rules out a solo vepdegestrant launch
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
Arvinas leader departs under a Pfizer-shaped cloud
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
